BONE MARKERS IN THE REGULATION OF OSTEOPOROSIS ASSOCIATED WITH PREGNANCY AND LACTATION
Keywords:
osteoporosis associated with pregnancy and lactation, RANKL, OPG, β-cross lapsAbstract
Objective: Changes in bone density and bone markers suggest that pregnancy is associated with poorer maternal bone mass. Calcium metabolism is restored to meet the needs associated with the construction of the fetal skeleton. The fetus contributes to this process by removing regulators from the placenta. Understanding of the entire process is limited, but some changes are clear.
Aim: To study the influence of risk factors such as the OPG/RANKL ratio in the development of osteoporosis associated with pregnancy and lactation.
Materials and methods: To fulfill the objectives of the study, we formed 2 groups of subjects. The first, main group consisted of 27 women who developed back pain during pregnancy and/or lactation and an MRI study revealed compression fractures of the vertebrae of various locations. The second, control group consisted of 14 women without fractures and complaints of back pain in the anamnesis.
Results: A comparative analysis in the main and control groups showed that, depending on the activity of β-cross laps, the average OPG value in the main group of women with normal and increased bone tissue resorption was comparable. At the same time, the average RANKL values in the main group, in the subgroup with normal resorption, are significantly lower than in the group with increased resorption (1,74±0,51 and 0,78±0,18). The average RANKL values in the control group and in the subgroup with normal resorption are also lower than in the group with increased resorption (80,13±21,4 and 232,4±87,8). A comparative analysis of the OPG/RANKL ratio in the main group, in the subgroup with normal resorption was higher than in the subgroup with increased resorption and amounted to 0,025;0,0010 respectively. At the same time, in the control group there were no differences in subgroups. The OPG/RANKL ratio in women of the main and control groups with normal resorption was higher, and in the group with increased resorption this ratio was higher (0,025 and 0,01; 0,007 and 0,001).
Conclusion: Various methods of osteoclastic differentiation treatment are used as the main treatment method, such as induction of osteoclastic differentiation, research and modeling of osteoclastic differentiation. The main group of osteoprotegerin (OPG) contained 0.78 pg/ml, the control group 1.74 pg/ml (P=0.005) eddy. In the main group, the RANKL is 232.4 pg/ml, in the control group 80.13 =49.3 pg/ml (P=0.05) eddy. The main group of Ranklga osteoprotegerining, compared with the control group, has a low edi index close to a trillion (P = 0.01).
References
Boyce BF, Xing L. Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys. 2008 May 15;473(2):139-46. doi: 10.1016/j.abb.2008.03.018. Epub 2008 Mar 25. PMID: 18395508; PMCID: PMC2413418.
Boyce BF, Xing L. Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys. 2008 May 15;473(2):139-46. doi: 10.1016/j.abb.2008.03.018. Epub 2008 Mar 25. PMID: 18395508; PMCID: PMC2413418.
Briana DD, Boutsikou M, Baka S, Hassiakos D, Gourgiotis D, Malamitsi-Puchner A. Circulating osteoprotegerin and sRANKL concentrations in the perinatal period at term. The impact of intrauterine growth restriction. Neonatology. 2009;96(2):132-6. doi: 10.1159/000211666. Epub 2009 Apr 8. PMID: 19365143.
Findlay DM, Atkins GJ. Relationship between serum RANKL and RANKL in bone. Osteoporos Int. 2011 Oct;22(10):2597-602. doi: 10.1007/s00198-011-1740-9. Epub 2011 Aug 18. PMID: 21850548.
Hong JS, Santolaya-Forgas J, Romero R, Espinoza J, Gonçalves LF, Kim YM, Edwin S, Yoon BH, Nien JK, Hassan S, Mazor M. Maternal plasma osteoprotegerin concentration in normal pregnancy. Am J Obstet Gynecol. 2005 Sep;193(3 Pt 2):1011-5. doi: 10.1016/j.ajog.2005.06.051. PMID: 16157103; PMCID: PMC1351230.
Lonergan M, Aponso D, Marvin KW, Helliwell RJ, Sato TA, Mitchell MD, Chaiwaropongsa T, Romero R, Keelan JA. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), TRAIL receptors, and the soluble receptor osteoprotegerin in human gestational membranes and amniotic fluid during pregnancy and labor at term and preterm. J Clin Endocrinol Metab. 2003 Aug;88(8):3835-44. doi: 10.1210/jc.2002-021905. PMID: 12915677.
Naylor KE, Rogers A, Fraser RB, Hall V, Eastell R, Blumsohn A. Serum osteoprotegerin as a determinant of bone metabolism in a longitudinal study of human pregnancy and lactation. J Clin Endocrinol Metab. 2003 Nov;88(11):5361-5. doi: 10.1210/jc.2003-030486. PMID: 14602774.
Sanz-Salvador L, García-Pérez MÁ, Tarín JJ, Cano A. Bone metabolic changes during pregnancy: a period of vulnerability to osteoporosis and fracture. Eur J Endocrinol. 2015 Feb;172(2):R53-65. doi: 10.1530/EJE-14-0424. Epub 2014 Sep 10. PMID: 25209679.
Schramek D, Sigl V, Penninger JM. RANKL and RANK in sex hormone-induced breast cancer and breast cancer metastasis. Trends Endocrinol Metab. 2011 May;22(5):188-94. doi: 10.1016/j.tem.2011.02.007. Epub 2011 Apr 4. PMID: 21470874.
Sigl V, Penninger JM. RANKL/RANK - from bone physiology to breast cancer. Cytokine Growth Factor Rev. 2014 Apr;25(2):205-14. doi: 10.1016/j.cytogfr.2014.01.002. Epub 2014 Jan 10. PMID: 24486161.
